Figure 3
OS and time to AML progression in MDS patients. OS (A) and time to AML progression (B) in MDS patients with IPSS low/intermediate-1 risk according to SRSF2 mutation status (log-rank test) are shown.
OS and time to AML progression in MDS patients. OS (A) and time to AML progression (B) in MDS patients with IPSS low/intermediate-1 risk according to SRSF2 mutation status (log-rank test) are shown.
